The race to displace injectable biologics in severe asthma with a more convenient, durable inhaled therapy just got a major new contender. AirNexis Therapeutics has secured a $200 million Series B financing, a war chest that will directly fund a pivotal Phase 3 program for its lead asset, ANX-101. This drug is an inhaled small interfering RNA (siRNA) designed to silence the expression of IL-4Rฮฑ, a key node in the type 2 inflammatory pathway targeted by monoclonal antibodies like dupilumab. Early clinical data showed a compelling profile: significant reductions in exacerbations and improved lung function with quarterly nebulization, a stark contrast to the weekly or biweekly injections of current standards.
The capital will be deployed to initiate two global Phase 3 trials in severe, uncontrolled asthma patients, with topline data expected in late 2028. A successful readout would position ANX-101 as a potential paradigm-shifter in a multi-billion-dollar market dominated by injectables. While the investor syndicate remains undisclosed, the sheer size of this private round suggests participation from top-tier crossover funds eyeing a near-term public offering, betting that the convenience of an inhaled RNA therapeutic can command premium pricing and rapid uptake.
This deal underscores a strategic pivot in respiratory drug development. It's not just another biologic; it's a direct application of RNA interference, a modality that has conquered the liver and is now aggressively targeting the lung. AirNexis's progress validates the lung as a viable target for locally delivered oligonucleotides, potentially opening the door for similar approaches in COPD, IPF, and beyond. The sector is watching: if ANX-101's Phase 3 data hold, it could trigger a wave of investment in inhaled nucleic acid therapies.